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Abstract  
The aim of this study was to explore Welsh adults’ experiences of the transition into 
survivorship from initial active systemic anti-cancer treatments for haematological 
cancers. An exploratory, qualitative descriptive study consisting of in-depth face to 
face interviews was designed. A convenience sample of adults in Wales, UK who had 
completed their initial anti-cancer treatment for haematological cancer was recruited 
from one University Health Board. Data were generated in digitally recorded, 
individual, face to face interviews during 2017. Interviews were fully transcribed and 
analysed using a qualitative thematic approach 
 
Seven people participated in interviews. Thematic analysis revealed three themes: 
Encountering ambiguity, the pursuit of normality and navigating treatment completion. 
The transition from patient to survivor was characterised by trepidation and 
uncertainty. While participants sought to resume a sense of normality in their lives they 
were beset by enduring treatment effects. They felt insufficiently prepared for these 
effects and were uncertain about the availability of ongoing supportive care which met 
their individual needs. Participants articulated that they desired much more from 
haematology providers in preparing them for life beyond initial cancer treatment.  
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Background 
Internationally, research has consistently shown that adults affected by 
haematological cancers have unmet needs across their illness trajectories.1,2,3,4,5,6,7 
Described as a mismatch between what individuals’ perceive as necessary to optimize 
their health and the care and services actually received1, unmet needs can impact 
negatively on health, wellbeing and life quality. Most studies conclude that people 
affected by haematological cancers are underserved and that to enhance survivorship 
outcomes supportive care interventions and care coordination must be improved. 
5,6,8,9,10   
 
While some newer haematological cancer treatments are less toxic,11 others are complex, 
intense, debilitating and burdensome.6,12,13 Treatment completion, also known as re-
entry14,15 is a transitional point in cancer trajectories. The end of treatment may be eagerly 
awaited and, when it arrives, marked by joy juxtaposed against relief. However, life will have 
changed and the known, trusted and reassuring safety net of treatments and attendant 
professional and peer support may have been cast away.10 There may be 
expectations, on several levels, of resuming normal life. Nevertheless, debilitating 
physical and/or psychological problems, for example, severe fatigue, persistent 
anxiety and uncertainty, can endure or even develop long after treatments 
cease.16,17,18,19 Furthermore, individuals may experience altered role and physical 
functioning, financial and employment concerns and relationship difficulties.1,16 With 
no clearly defined ending to their illness in sight and viewed through the lens of the 
theoretical concepts of liminality,20 and biographical disruption,21 individuals’ realities 
may be that on initial treatment completion they are caught between the binary of 
illness and wellness, ‘betwixt and between’ and living in an unknown, ambiguous, 
liminal place.  
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International research has documented the myriad of challenges experienced, often 
unexpectedly, in the aftermath of initial cancer treatment.22,23,  These include feeling 
unprepared,24,25,26,27 experiencing uncertainty,24,26,28 fear of recurrence24,26,28,29 and 
being insufficiently informed about late treatment effects,24,26 self-management 
strategies and local support services.24 However, for people affected by 
haematological cancers this distinct point in the illness trajectory is still poorly 
understood, for it remains relatively unexplored. Yet the experiences of and issues for 
people living with and beyond haematological cancers are increasingly relevant, not 
least because their incidence and prevalence are steadily rising globally.30,31 While 
clinical outcomes vary across the numerous haematological cancer sub-types,30,32,33. 
the United Kingdom has 44,390 new cases annually, five year prevalence is 163,80011 
and survival across most of Europe is improving.34 The population of people living with 
and beyond haematological cancer is therefore growing, a trend which will continue 
with ageing, improving detection and treatment advances.12,34 Better understanding of 
individuals’ experiences in the immediate aftermath of treatment completion is 
required to provide insight and information to guide person-centred service 
enhancement. Accordingly, this paper reports findings from a qualitative study 
conducted in the devolved nation of Wales, UK which sought to obtain in-depth 
understanding of adults’ experiences of their transition from initial active treatment for 
haematological cancers into survivorship.  
Method 
As this was an exploratory study, a qualitative descriptive design35 using in-depth 
interviews and thematic analysis was adopted. The study was conducted in Wales, 
United Kingdom. Following approvals from National Health Service and health board 
research ethics and governance, individuals with haematological cancers who had 
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completed initial active anti-cancer treatment were recruited. Adults meeting the 
inclusion criteria (table 1) were identified by oncology outpatient clinicians and given 
a study pack comprising an invitation letter, study information sheet and response slip 
to return directly to the researcher (JB) if they were interested in taking part.  
Please insert table 1 here 
With participants’ consent, in-depth, face to face, digitally recorded interviews were 
conducted in 2017 in a location of participants’ choosing. Interviews have a long 
history in qualitative research and are used extensively to generate rich data that 
confers insight into experiences, thoughts, feelings and interpretations.36 Interviews 
were aided by a loose interview guide (Table 2) derived from the literature and 
consultation with service users.  
Please insert table 2 here 
Interviews were fully transcribed. To protect anonymity, all participants were allocated 
a unique pseudonym known only to the researcher. Transcribed data were analysed 
using an analytic framework37 widely used in qualitative research. This systematic, 
approach involves searching for patterns of meaning across the dataset. Transcripts 
were repeatedly read to ensure data familiarisation and then manually coded. Codes 
were abstracted into sub-categories, categories and broad overarching themes and 
scrutinized for similarity and duplication.  
 
Trustworthiness was enhanced by drawing on measures to achieve credibility, 
transferability, dependability and conformability.38 Meticulous transcription and 
checking of interviews and rigorous data analysis by two researchers independently 
contributed to credibility. Detailed descriptions of experiences aided transferability 
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whilst an audit trail of methodological decisions ensured dependability and 
confirmability. 
Results 
Eight people expressed an interest in participating in the study and seven were 
interviewed: three women and four men, who were between eight months to three 
years post active treatment. Two participants had undergone stem cell transplant while 
others had received either chemotherapy alone or in combination with Rituximab. The 
interviews lasted between 35 and 45 minutes.  
 
Three key themes were identified from data analysis: “Slightly unsure”?: Encountering 
ambiguity; “Trying to get back to my normal”: the pursuit of normality; “What happens 
now”?: navigating treatment completion. 
Slightly unsure: Encountering ambiguity. 
Treatment completion was a celebrated milestone for it marked an important juncture 
in participants’ cancer journeys. However, while it was met with thanks, gladness and 
relief there was also a deep sense of trepidation. Indeed, cast adrift from the 
surveillance and relative safety of the specialist centre with its intensive professional 
and peer support, participants were uneasy about their future, not least because they 
were concerned their cancer could return. 
Participants had welcomed treatment completion, for, as Annie explained, during 
treatment “you just feel like it’s the end.” This eagerly awaited milestone meant the 
cessation of intensive, debilitating and for some even “traumatic” interventions:  
I was praying for the last one [treatment] to come along (….).A sense of relief I 
guess it was that it [treatment] was over.  (…) I had got to the stage where I was 
dreading coming up. (…) (Christopher) 
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However, there was a sense of loss at leaving the treating team’s safety net of constant 
surveillance and the supportive bonds cultivated therein. The magnitude of loss is 
encapsulated in the metaphorical language in following data excerpts:  
You are in this umbrella and you want to stay here and see people here. (Christopher) 
I felt I lost part of me like, cos I look upon, up here as a part of your home, not a 
home, but a group, somebody to talk to, same conditions as you. (Gareth)  
Despite their supportive families, many participants felt “alone and lost” (Annie) and 
extremely vulnerable at this juncture. There was a palpable sense of insecurity and 
enduring ambiguity about the future. The possibility of recurrence or relapse and 
awareness of mortality permeated participants’ accounts. Some openly expressed 
these anxieties:   
It’s always in the back of your mind. I get a bit depressed, and I think is it going 
come back? When’s it going to come back? How long have I got? (Gareth)  
You begin to wonder, is this the end or is this the start of another session of 
it? [cancer]. (Bill) 
  
For others, anxiousness about possible recurrence or relapse was manifest in the 
vocabulary that cancer was ever present:  
It’s there somewhere in my body it’s probably a little cyst or something. (Debbie) 
I think it’s a thing at arm’s length at the moment. It’s in me but it’s under control 
(Christopher)  
 
“Trying to get back to my normal”: the pursuit of normality; 
Despite a prevailing sense of ambiguity, when treatment ended participants prioritised 
recovery and a return to normality. Yet there were limits to what participants could 
realistically and comfortably achieve. To find a way through participants drew on 
different self-management strategies and, through a process of acceptance and 
readjustment, their normal was redefined.  
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Participants’ accounts indicated that treatment completion signalled time for recovery 
and attempting to restore and maintain a sense of normality: 
Trying to go back to normal and do what you normally do. (Annie) 
They spoke of resuming everyday activities, routines, hobbies and taking holidays. 
For those who were employed (n=2), returning to work was important, for it would 
provide structure, support and financial stability. Nevertheless, workplace 
reintegration was contingent on supportive, facilitative and flexible employers:  
They [employer] put me on a phased return which was over a period of 
eight weeks, and I started doing 4 hours a day, for two weeks then 5 then 6 then 
7, so it was over about ten weeks. And I am back to full time now. (Christopher)  
 
In contrast Annie described her “shock” and heartbreak at discovering that following 
treatment she was unable to return the job she “loved.” Her distress was amplified by 
the felt stigma of being reliant on state welfare, her perception of “scrounging” and the 
haunting of the humiliating words that she was no longer “fully functional.”  
To say you are not fully functional is like a bombshell, it’s like a punch in the face. 
That was hard and I don’t think I will ever get to terms with that. (Annie)  
This experience left an indelible mark on Annie’s sense of self and identity. Yet despite 
her heartache Annie described how she tried to play down the impact of what was 
happening by projecting an aura of normality:  
Trying to put a brave face on things and people around you. You try not to affect 
them or hurt them. And that’s hard. And to be positive. That’s the hardest thing I 
have ever done. (…). My daughter is with me all the time and I pass things off oh 
‘I’ll be fine’ you know but deep inside you are suffering like anything. (Annie) 
 
Annie’s words convey she engaged in hard work, regulating and managing her 
emotions to protect her family. The work of constructing an outward image of normality 
in the face of adversity and precariousness was not unusual. The words “I am fine,” 
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conveyed a finely veiled message of normality through participants’ accounts. 
Sometimes however, participants chose to remain silent:  
        [I] keep it to myself, I wouldn't say much to my wife.  
Is that a conscious decision?  
Yeah I think it is, because I don't know. I don't want to burden and worry people, 
because I know my wife, she would worry about anything. (Harry)   
 
Constructing an outward image of normality enabled participants to maintain a sense 
of control. Yet after treatment ended unpleasant, debilitating treatment effects lingered 
on or even emerged. In the main these effects were physical and psychological and 
included fatigue, nausea, insomnia, anxiety and low mood. An “overriding feeling of not 
being well” prevailed, imposing unanticipated enduring disruption in participants’ lives: 
I couldn’t even climb the stairs, no energy, no nothing. Couldn’t even dress, wife 
had to undress me, shove me in bed. Climb halfway up the stairs, sit on the step,10 
minutes up to the top step, stop for ten minutes, sit on the bed. (Gareth) 
 
I wasn't buoyant anymore (….) I got a little bit down and I think I was depressed, 
and there was all sort of niggly bits starting I didn't I didn't pick up my tai chi sport, 
(….) I was beginning to get isolated. I would only go out with my husband and didn't 
go off on my own like I was used to. (Ffion)  
Against this background and to facilitate recovery, adjust and restore some semblance 
of a normal life, participants drew on different self-identified self-management practices 
contingent with their needs, goals and understandings. Some turned to positive 
lifestyle modifications in terms of smoking cessation, reduced alcohol intake, physical 
activity and improved diet:    
I do the exercise they told me, I stand up and do the standing up press ups. (….). 
I don't know how many stairs I have done today? I’m useless on this bloody 
watch (…), 15 floors. Sometimes I do 50 odd. And what steps? 5000 
steps. (Harry)  
I try to keep myself healthy by eating healthy. (….). I probably eat a bit differently 
I think, because now I have cereal and yoghurt in the morning (…)and I don’t eat 
so much junk food. Because you think it’s important to try and keep your body 
healthy. (Annie) 
 
To mitigate worry online forums and third sector support were accessed:  
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I joined a lymphoma society online (…) and I found that a godsend, there is a hell 
of a lot of information on that and you just type in, there’s forums there, there are 
people there with the same condition as you, people with the same problems. 
(Gareth) 
Participants also reappraised their lives, priorities and relationships for their illness had 
made them think about what was important, what mattered and living in the moment: 
Now I think no, this is my life and I have got to live it the way I want to live it. 
(Ffion) 
I want to get everything done, now, because you don't know how long before it 
comes back, if it comes back. (Gareth) 
Thus, an enduring sense of illness meant that through adjustment and acceptance, 
normal was redefined and gave way to a new normal: 
 You’ve got to learn to live with and cope with it (…). Try to do things that I normally 
do but you know I can’t always do everything that I want to do but I do try. (Annie) 
“What happens now”?: navigating treatment completion. 
Participants had felt unprepared for the enduring treatment effects and isolation 
experienced in the aftermath of treatment completion. They identified a pressing need 
for enhanced continuing supportive care, preferably, but not exclusively provided by 
the specialist treatment team. 
 
Some were prepared to tolerate the problems they were experiencing for they had 
been left with the gift of life and a second chance. However, insufficient specific 
preparation for enduring and late treatment effects threaded through participants’ 
accounts:  
You would walk. You would go up a path and up another path, and I was having to 
stop twice and I thought what the hell is going on here? (….). I did talk to them 
[doctors] about it. He [doctor] told me that chemotherapy can attack organs in your 
body. Well I said, no-one told me that. (…) I would have liked for someone to say, 
you could have problem with some of your organs in your body. (Harry) 
 
In the beginning [of treatment] the set up was wonderful and [nurse] gave me all 
these things and the information and the phone numbers in case things went 
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wrong (….). But there was not much afterwards, information. That I might feel 
depressed or down, can’t sleep, I mean worrying. (…). I didn't know what to 
expect. (Ffion) 
 
Participants felt ongoing surveillance by their haematology doctors via routine medical 
follow-up clinics was reassuring. They were acutely aware that clinics were extremely 
busy places and were immensely grateful to be seen. However, they felt the quality of 
the consultation was limited for it was rushed, biomedically driven and doctor led and 
primarily focused on reviewing blood results:  
I know there is a lot of people to see but I think it could do with somebody  with a 
bit more time with you. To say how you are feeling, because when you come for 
an appointment here it’s sort of ‘how are you today?’ blah blah and that’s it and 
you are out. (Annie) 
Participants’ felt that the physical and psychological issues they were experiencing 
were perceived to be of secondary importance and thus held in abeyance:    
[Doctor] is very to the point, and I found if you spoke about anything else at times 
you would almost feel you were in the wrong for asking that type of questions 
(Christopher) 
 
 
While participants spoke affectionately about their General Practitioners, there was 
uncertainty as to whether they were suitably positioned to meet their needs. Indeed, 
participants described the busyness, lack of specialist knowledge and discontinuity in 
GP services:  
They [GP’s] are overworked as well. So, do they really understand the in-depth 
of what’s going on within the body? (Ffion) 
 
The trouble is now we've got this system where you go in and you don't know who 
you gonna see. With a regular one [GP] you could talk to them (…). (Debbie)   
All participants articulated the need for enhanced supportive care following treatment 
completion. While views on the precise nature of supportive care desired varied, the 
prevailing viewpoint was that it should be provided by the specialist treatment team. 
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This was because participants trusted and had confidence in the team’s knowledge, 
skills and expertise: 
The first thing I would do is get in touch with you lot up here you. You lot know 
what you are doing and I would think I want to start there.  I could start at the 
doctors but all he would be doing is referring to you, I think, I would want to go 
straight to the horse’s mouth to the people who are supposed to know. (Bill) 
 
At the same time high value was placed on peer support, speaking with others who 
had also been through the treatment experience either on a one to one or group basis:  
A support group would be a good thing where they can talk about how they feel in 
front of other people because I think people are probably more open if that was 
there, and  you think ‘oh actually’ and then you can help someone else as 
well. (Annie) 
Participants also described a need for better information on treatment completion and 
made their own suggestions on what could be valuable in supporting the transition into 
survivorship: 
Is there a possibility that they [patients] can have some information that you can 
give them?  Some little bit and you can say ‘that’s what you can do?’ (Ffion) 
 It’s quite easy to get a piece of paper and you put it in a folder or whatever and you 
just forget about it until you need it. [People] should be aware (…) bits that you 
need to really know. (Annie) 
 
Discussion 
The findings from this interview study revealed that on treatment completion 
participants encountered enduring, unanticipated disruption in their lives. They felt 
unprepared for the transition and treatment effects and although self-management 
strategies were embraced there was a perception of inadequate continuing 
professional support. This study adds to the limited existing literature describing the 
experiences of adults who have competed initial treatment for haematological cancers 
at what is a key transitional point. The findings have value as they offer specialist 
haematological staff rich insight into the challenges people encounter on initial 
treatment completion, their unmet supportive care needs and why and how they feel 
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these may be addressed. The findings are important because they unveil that people 
with haematological cancers are still insufficiently prepared for life beyond treatment 
and available support. Accordingly, the findings will be valuable in driving and 
supporting innovation in high quality, individualised, person-centred service provision 
for survivorship care at a critical juncture.  
 
The strength of this study is the generation, through in-depth interviews, of rich, 
detailed narratives which encompass the breadth of individuals’ unique experiences 
at this key transitional point in their cancer journey. Nevertheless, the study has 
limitations for it reflects insights of a small, heterogeneous sample of self-selecting 
participants at one time point and in one geographical area. Yet sample size is not a 
methodological limitation for it is in accord with exploratory qualitative research and in 
terms of meeting the study's aims adequate. Furthermore, findings are not intended to 
be representative and generalized to the wider population.  While recall accuracy must 
be considered, insights are valuable, have commonality, and connect with findings 
from previous research. 
 
Participants’ vocabulary affirmed they welcomed initial treatment completion. While 
treatment had been traumatic and disrupted their lives, this had been mediated by the 
intense, continuous surveillance and support of the specialist treatment team. Follow 
up notwithstanding, discharge meant this level of surveillance ended. The magnitude 
of the personal sense of loss experienced at this point is made visible in participants’ 
metaphorical language and the implication that without the treating team’s support 
they felt different, fragmented and no longer whole.  
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As in previous studies,4,29 data revealed that treatment completion generated 
disruption and concern. Worry about the possibility of relapse or recurrence and 
awareness of mortality cast lasting shadows. In the absence of intensive specialist 
surveillance and reflecting findings from previous studies7,39,40 this worry was a 
disruptive force. It rendered participants vulnerable, emotionally and existentially, and 
engendered a profound sense of ambiguity about their futures. There is a sense in 
which the disruption they experienced constituted a biographical disruption, for their 
life, hopes and self-concept had altered.21 Furthermore, being shrouded in ambiguity 
and drawing on the anthropological work of van Gennep41 and Turner,20 participants 
found themselves in a liminal state for they were betwixt and between the binary of 
being ill and being completely well.  
 
Participants’ everyday lives had been fractured by cancer and its punishing treatment. 
In the liminal space of treatment aftermath, and consistent with previous research,42 
active pursuit and resumption of normality were core priorities. Participants’ accounts 
indicated that they exercised agency and worked hard to resume routine activities, 
family and work responsibilities, a finding which resonates with those from earlier 
studies.42,43,44,45 Attempting to assert some continuation with the biographical 
trajectory of life before illness may be connected with societal expectations, and thus 
tacit pressures, to resume normal life.46 Furthermore, resuming routine activity is an 
important phase in recovery, a powerful symbol of normality and may convey a 
‘restored self.’47 Yet the data revealed that attempts to resume normal life were not 
always successful. The inability to meet self and others’ expectations could shatter an 
individuals’ sense of self and, drawing on Bury,21 sustain biographical disruption. Even 
so, despite the underlying disruption and resonating with findings from previous 
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studies,48,49 some individuals engaged in difficult emotion work to maintain an external 
aura of normality and protect themselves and those they loved.  
 
The myriad of unanticipated, enduring treatment effects, which did not always subside 
with the passage of time, had a profound impact on participants’ lives, general sense 
of well-being and thus normality. To reclaim a sense of normality and self and reflecting 
findings from earlier studies48 participants were motivated to practice self-
management to promote and enhance their recovery. Self-management was 
perceived as a way of reinstating a sense of control of their health and physical and 
psychological wellbeing and reintegrating with their social world. The quest for 
normality is consistent with findings from previous studies.29,42,48 Yet being well, yet 
unwell, disruption persisted and while normality was reconstructed and redefined 
participants remained caught in a liminal space. 
 
The complex, potent amalgamation of psychological suffering, enduring physical 
symptoms and impaired role and social functioning signals the need for and 
importance of proactive, person-centred supportive interventions in the immediate 
post treatment phase. Indeed, the Institute of Medicine50 noted the criticality of the 
transition from the treatment to post cancer treatment phase. Nevertheless, our data 
revealed that while participants valued scheduled, consultant led follow up and held 
their General Practitioners in high regard, many still felt cast adrift, isolated, vulnerable 
and generally unsupported by the healthcare system. This is consistent with findings 
from previous studies2,51 and to some extent relates to the biomedical as opposed to 
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experiential person-centred focus of routine follow up and acknowledgement that 
General Practitioners do not have specialist knowledge. 
 
Unlike findings from an earlier study42, participants wanted some form of ongoing 
personalised support to enable them to live with the everyday challenges they faced. 
An unexpected finding was that while support was available locally our data revealed 
participants’ were unaware of this. At first sight this may be read as suggesting 
difficulty with accessing information and navigating the system. However, an 
alternative reading, drawing of the work of Swash et al.2 is the possibility that existing 
services were designed around the totality of cancer support services and therefore 
perceived by our participants as irrelevant. 
 
The findings signal and reinforce the importance of embedded, systematic, proactive 
approaches to care in the shape of integrated, person-centred recovery packages. 
These interventions may enable people to begin to plan for and navigate the unknown 
territory of life in ‘remission society’52 and begin to make a positive difference to patient 
reported outcomes in terms of long term quality of life and wellbeing. Through early 
identification of holistic needs, information sharing, coordination and supported self-
management, people in the post initial treatment phase may be activated and 
empowered to become proactive partners in care: planning and using individual 
strategies which will enable them to optimise and maintain their health, wellbeing and 
quality of life. 
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Conclusions 
Our findings suggested that on treatment completion participants’ experienced a 
lasting struggle for they had unmet supportive care needs and were uncertain of 
where to turn. They desired much more in the way of ongoing supportive care. 
Haematology providers have a critical role to play in preparing these people for life 
beyond their treatments and ensuring that they are cognizant of potential long term 
and late effects, supportive care and different self-management strategies. To ensure 
people are not lost in transition specialist nurses working across care boundaries are 
well placed to have important and influential roles in facilitating recovery in terms of 
building self-efficacy, ensuring continuity and coordination of care and enabling 
access to services. Nevertheless, empirical investigation is required to capitalize on 
the findings reported here.  
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Table 1: inclusion and exclusion criteria 
 
Inclusion 
criteria 
 
• Over 18 years of age. 
• Diagnosed with and treated for a haematological malignancy.  
• At least six months post initial SACT completion. 
• Willing to participate and be interviewed in the English language. 
• Able to give informed consent. 
 
 
Exclusion 
criteria 
 
 
• Unwilling or unable to participate. 
• Still receiving SACT. 
• Unable to give informed consent 
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Table 2. Loose interview guide  
 
interview guide 
 
 
Discussion of experiences of treatment 
Discussion of feelings and experiences on completion of treatment.  
Discussion of experiences of follow up and recovery, including support systems 
accessed.  
Views on enhancing the organisation and delivery of supportive care post initial 
treatment. 
Anything else that they would like to share 
  
Clarification will be sought as necessary to enrich the descriptions 
 
 
 
 
